Literature DB >> 18475544

Nitrite is produced by elicited but not by circulating neutrophils.

A G Stewart1, G J Dusting, R G Giarracca, T Harris, Y Lim, C G Sobey.   

Abstract

The generation of nitrite (NO(2) (-)) was used as an index of the production of nitric oxide by human and rat polymorphonuclear leukocytes (PMN) and rat peritoneal macrophages. Human peripheral blood PMN did not produce significant levels of NO(2) (-). Attempts to induce NO(2) (-) generation in human PMN by incubation with GM-CSF (1 nM), TNFalpha (0.3 nM), endotoxin (1 mug/ml) or formyl-Met-Leu-Phe (100 nM) for up to 16 h were not successful. Addition of human PMN primed by GM-CSF (1 nM) to rabbit aortic ring preparations precontracted with phenylephrine had no effect on tone. In contrast to these observations, PMN, isolated from the peritoneum of oyster glycogen treated rats, generated NO(2) (-) via a pathway sensitive to inhibition by the nitric oxide synthase inhibitor, N(G)-monomethyl L-arginine. However, peripheral blood rat PMN obtained from the same animals did not produce NO(2) (-), even during prolonged incubation for periods of up to 16 h. It is suggested that detectable NO production by PMN requires NO synthase activity to be induced either by the process of PMN migration or by exposure to certain cytokines produced locally at the site of inflammation.

Entities:  

Year:  1993        PMID: 18475544      PMCID: PMC2365423          DOI: 10.1155/S0962935193000481

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  37 in total

1.  Three regulation mechanisms of nitric oxide synthase.

Authors:  K Hiki; Y Yui; R Hattori; H Eizawa; K Kosuga; C Kawai
Journal:  Eur J Pharmacol       Date:  1991-02-25       Impact factor: 4.432

2.  Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages.

Authors:  S S Gross; E A Jaffe; R Levi; R G Kilbourn
Journal:  Biochem Biophys Res Commun       Date:  1991-08-15       Impact factor: 3.575

3.  Identification of N-iminoethyl-L-ornithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells.

Authors:  T B McCall; M Feelisch; R M Palmer; S Moncada
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

4.  Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.

Authors:  D D Rees; R M Palmer; R Schulz; H F Hodson; S Moncada
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

5.  Calmodulin-independent nitric oxide synthase from rat polymorphonuclear neutrophils.

Authors:  Y Yui; R Hattori; K Kosuga; H Eizawa; K Hiki; S Ohkawa; K Ohnishi; S Terao; C Kawai
Journal:  J Biol Chem       Date:  1991-02-25       Impact factor: 5.157

6.  Involvement of leukotriene B4 and platelet-activating factor in cytokine priming of human polymorphonuclear leucocytes.

Authors:  A G Stewart; T Harris; M De Nichilo; A F Lopez
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

7.  Vimentin is transiently co-localized with and phosphorylated by cyclic GMP-dependent protein kinase in formyl-peptide-stimulated neutrophils.

Authors:  T A Wyatt; T M Lincoln; K B Pryzwansky
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

8.  Tumour necrosis factor alpha augments the release of an endothelium-dependent vasoconstrictor from human polymorphonuclear leukocytes.

Authors:  C G Sobey; G J Dusting; A G Stewart
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

9.  Adenosine inhibits platelet-activating factor, but not tumour necrosis factor-alpha-induced priming of human neutrophils.

Authors:  A G Stewart; T Harris
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

10.  Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide.

Authors:  N S Kwon; D J Stuehr; C F Nathan
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.